BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study

• DOI: 10.1016/j.vaccine.2024.04.047
• Publication Date: 2024-04-21T05:02:27Z
• Authors: Sanjin Musa; Lore Merdrignac; Sinisa Skocibusic; Rozalija Nedic; Seila Cilovic-Lag...; Esther Kissling
• Keywords: Clinical endpoint

COVID-19 vaccine uptake in the Federation of Bosnia and Herzegovina (FBiH) accelerated second half 2021, with greater availability. In this study, we estimated effectiveness (VE) complete primary series BBIBP-CorV against patients aged 60 years older, during Delta-dominant period, using a test-negative case-control design. Surveillance sites were 11 health care centers (PHC) collecting patient data from October 1, to January 4, 2022, retrospectively according common protocol. total, included 1711 participants analysis: 933 cases 778 controls. Of cases, 508 (54.4 %) had mild 425 (45.6 moderate severe disease presentation. We observed no COVID-19. Overall was 65.0 % (95 %CI: 40.1–79.5) time since vaccination analysis, VE 78.7 CI: 54.8–89.9) who received their last dose < 90 days before onset; 66.0 −0.5–88.5) those 90–119 42.1 −88.6–82.3) 120–149 onset 45.0 −94.0–84.4) ≥ 150 onset. our two doses provided considerable protection older adults, highest within 3 months after dose, period. Point estimates declined thereafter, suggesting need for additional doses.